BioSpace News Archive

GSK Consumer Healthcare, the makers of Voltaren Arthritis Pain Gel revealed new data that uncovers a painful truth: for people with osteoarthritis, mornings can be the most difficult part of the day.

- Dr. Morich is an industry leader with over 35 years of experience in biopharmaceuticals with focus in commercialization, R&D and product development - - Previously served as Chief Commercial Officer of Takeda Pharmaceutical Company, Chief Executive Officer of Takeda Pharmaceutical International, Chief Executive Officer of NOXXON Pharma AG, Chief Executive Officer of Innogenetics N.V., and Head of Global Product Development of Bayer AG Pharmaceutical Division -

St. Elizabeth’s Medical Center announced a new academic and clinical affiliation with the Boston University School of Medicine that will bring enhanced, innovative medical education and clinical research opportunities to Steward Health Care’s flagship tertiary care facility.

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Ken Londoner, Chairman and CEO of BioSig Technologies, Inc. will provide a keynote update during the Wall Street Conference on Wednesday, May 5, 2021, at 12:05 pm ET.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound IM156, an investigational Protein Complex 1 (PC1) inhibitor, being evaluated for idiopathic pulmonary fibrosis (IPF).

300,000 Canadians are living with type 1 diabetes (T1D). There is no known cause or cure, and the number of new cases is increasing by approximately 5% every year in Canada, with an annual health care cost of over $16 billion*.

AditxtScore™ Center is the first of a planned immune monitoring network and will initially monitor COVID-19 immunity status New facility expects to target more than 300 jobs over three years to the area

The Nagourney Cancer Institute announced that as part of its efforts to advance the understanding of human metabolism and the pivotal role that it plays in cancer, it will benefit from the Rosalie and Harold Rae Brown Foundation’s $2 million gift to The Vanguard Cancer Foundation.

Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care.